Phase 2 Kidney Cancer Trial, Recruiting NCT05842044 Sponsor: University of Miami Condition: Kidney Cancer
Back to Kidney Cancer

Phase 2 Kidney Cancer Trial, Recruiting

NCT05842044
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are scheduled to have an uncomplicated robotic-assisted keyhole surgery to remove part of a kidney for a kidney mass at the University of Miami Hospital or one of its network locations (Deerfield Beach, Plantation, Lennar/Coral Gables, or Kendall).
  • People aged 18 to 99 years old.
  • People who are able to understand and are willing to sign a written consent form agreeing to take part.

Who may not be able to join:

  • People who have an allergy to NSAIDs (a common type of pain relief medication, such as ibuprofen).
  • People who have had a heart attack or unstable chest pain within the last 12 months.
  • People who have ever had coronary artery bypass graft (open-heart bypass) surgery.
  • People with a history of or currently active stomach ulcers, gastrointestinal bleeding, or a hole in the stomach or bowel.
  • People with a history of a bleeding disorder.
  • People whose kidneys are not filtering blood well enough, based on a specific kidney function measurement (confirm with trial site).
  • People who are currently taking blood-thinning or anti-clotting medications, such as warfarin, aspirin, clopidogrel, or rivaroxaban.
  • People who have used opioid pain medications in the past 12 weeks or have a history of opioid use disorder.
  • People who only have one kidney.
  • People who are pregnant.
  • People who are unable to give informed consent or cannot meet the study requirements for any reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Mark L Gonzalgo, MD, PhD, University of Miami

Phone: 305-243-3246

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
15 September 2023
Est. completion
30 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Rate of Opioid Use in Postoperative Period

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov